References
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
- Institut National du Cancer, Institut National de Veille Sanitaire. Projection de l'incidence et de la mortalité par cancer en France en 2011. Rapport technique, Juin2011.
- Moreau P, Avet-Loiseau H, Harousseau JL, et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011;29:1898–1906.
- Roussel M, Facon T, Moreau P, et al. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent Results Cancer Res 2011;183:189–206.
- Boyd KD, Davies FE, Morgan GJ. Novel drugs in myeloma: harnessing tumour biology to treat myeloma. Recent Results Cancer Res 2011;183:151–187.
- Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011;17:1264–1277.
- Moehler T, Goldschmidt H. Therapy of relapsed and refractory multiple myeloma. Recent Results Cancer Res 2011;183:239–271.
- Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.
- Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
- Avis de la Commission de la Transparence, Velcade [Internet]. Saint-Denis La Plaine: Haute Autorité de Santé [cited 2012 October 18]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/ct031654.pdf
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
- Freimann H, Calderoni A, Cornu P, et al. Daily practice use of bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly 2007;137:317–322.
- Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316–1319.
- Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.
- Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–3560.
- Bogner C, Peschel C, Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma 2006;47:195–205.
- Smith D, Terrebonne E, Rouyer M, et al. Chemotherapy and targeted agents for colorectal cancer in a real-life setting anticipate guidelines: the COLCHIC cohort study. Fundam Clin Pharmacol 2013;27:113–119.
- Saad AA, Sharma M, Higa GM. Treatment of multiple myeloma in the targeted therapy era. Ann Pharmacother 2009;43:329–338.
- Fourrier-Reglat A, Droz-Perroteau C, Benichou J, et al. Impact of prescriber nonresponse on patient representativeness. Epidemiology 2008;19:186–190.
- Estimation de l'incidence et de la mortalité par cancer en France de 1980 à 2005 - Myélome multiple [Internet]. Saint-Maurice: Institut National de Veille Sanitaire; 2005. Available from: http://www.invs.sante.fr/surveillance/cancers/estimations_cancers/donnees_localisation/myelome/default.htm